Search
08/04/2023
Circulating progranulin in human infants: relation to prenatal growth and early postnatal nutrition
Diaz, M, Mestres-Arenas, A, Lerin, C, Cereijo, R, Lopez-Bermejo, A, de Zegher, F, Villarroya, F, Ibanez, L. Circulating progranulin in human infants: relation to prenatal growth and early postnatal nutrition. PEDIATRIC RESEARCH. 2023; 94(3)DOI:10.1038/s41390-023-02595-1. PMID:37031297. IF:3.100(Q1/2D).
29/03/2023
Who is lost to follow-up in HIV care? Assessment of care retention over time and the impact of COVID-19. Longitudinal analysis of the PISCIS cohort
Palacio-Vieira J., Moreno-Fornés S., Díaz Y., Aceitón J., Bruguera A., Nomah D.K., Llibre J.M., Knobel H., Chivite I., Miro J.M., Domingo P., Suanzes P., Fanjul F., Navarro G., Macorigh L., Mera A., Casabona J., Imaz A., Reyes-Urueña J.. Who is lost to follow-up in HIV care? Assessment of care retention over time and the impact of COVID-19. Longitudinal analysis of the PISCIS cohort. HIV MEDICINE. 2023; 24(9)DOI:10.1111/hiv.13486. PMID:36990962. IF:2.800(Q2/5D).
02/03/2023
Meteorin-like levels are associated with active brown adipose tissue in early infancy
Garcia-Beltran, C, Navarro-Gascon, A, Lopez-Bermejo, A, Quesada-Lopez, T, de Zegher, F, Ibanez, L, Villarroya, F. Meteorin-like levels are associated with active brown adipose tissue in early infancy. Frontiers in Endocrinology. 2023; 14DOI:10.3389/fendo.2023.1136245. PMID:36936161. IF:3.900(Q2/3D).
01/03/2023
Limited Weight Impact After Switching From Boosted Protease Inhibitors to Dolutegravir in Persons With Human Immunodeficiency Virus With High Cardiovascular Risk: A Post Hoc Analysis of the 96-Week NEAT-022 Randomized Trial
Waters, L, Assoumou, L, Gonzalez-Cordon, A, Rusconi, S, Domingo, P, Gompels, M, de Wit, S, Raffi, F, Stephan, C, Masia, M, Rockstroh, J, Katlama, C, Behrens, GMN, Moyle, G, Johnson, M, Fox, J, Stellbrink, HJ, Guaraldi, G, Florence, E, Esser, S, Gatell, JM, Pozniak, A, Martinez, E. Limited Weight Impact After Switching From Boosted Protease Inhibitors to Dolutegravir in Persons With Human Immunodeficiency Virus With High Cardiovascular Risk: A Post Hoc Analysis of the 96-Week NEAT-022 Randomized Trial. CLINICAL INFECTIOUS DISEASES. 2023; 76(5)DOI:10.1093/cid/ciac827. PMID:36259527. IF:8.200(Q1/1D).
01/01/2023
Obesity-Related Single-Nucleotide Polymorphisms and Weight Gain following First-Line Antiretroviral Therapy
Berenguer J., Jarrín I., Bellón J.M., Díez C., Jiménez-Sousa M.A., Roca C., González-García J., Dalmau D., Olalla J., Herrero C., Villarroya F., Domingo P., Resino S.. Obesity-Related Single-Nucleotide Polymorphisms and Weight Gain following First-Line Antiretroviral Therapy. CLINICAL INFECTIOUS DISEASES. 2023; 76(6)DOI:10.1093/cid/ciac880. PMID:36345912. IF:(Q/D).
01/01/2023
Cardiovascular events in delayed presentation of HIV: the prospective PISCIS cohort study
Martín-Iguacel R., Vazquez-Friol M.C., Burgos J., Bruguera A., Reyes-Urueña J., Moreno-Fornés S., Aceitón J., Díaz Y., Domingo P., Saumoy M., Knobel H., Dalmau D., Borjabad B., Johansen I.S., Miro J.M., Casabona J., Llibre J.M.. Cardiovascular events in delayed presentation of HIV: the prospective PISCIS cohort study. Frontiers in Medicine. 2023; 10DOI:10.3389/fmed.2023.1182359. PMID:37415770. IF:3.100(Q1/2D).
01/11/2022
Analysis of the costs associated with the follow-up of HIV patients discontinuing antiretroviral treatment due to lack of effectiveness or unacceptable toxicity in Spain
Castro, A, Diaz, P, Domingo, P, Garcia-Yubero, C, Losa-Garcia, JE, Castro, A, Vidal-Vilar, N, Aceituno, S. Analysis of the costs associated with the follow-up of HIV patients discontinuing antiretroviral treatment due to lack of effectiveness or unacceptable toxicity in Spain. Farmacia Hospitalaria. 2022; 46(6)DOI:10.7399/fh.13038. PMID:36520571. IF:(Q/D).
01/11/2022
Differential effects of dolutegravir, bictegravir and raltegravir in adipokines and inflammation markers on human adipocytes
Domingo, P, Quesada-Lopez, T, Villarroya, J, Cairo, M, Gutierrez, MD, Mateo, MG, Mur, I, Corbacho, N, Domingo, JC, Villarroya, F, Giralt, M. Differential effects of dolutegravir, bictegravir and raltegravir in adipokines and inflammation markers on human adipocytes. LIFE SCIENCES. 2022; 308DOI:10.1016/j.lfs.2022.120948. PMID:36096241. IF:6.100(Q1/2D).